AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2

Switglim MV 1mg/500mg/0.2mg Tablet ER

Prescription Icon
Prescription Required

Marketer

Akumentis Healthcare Ltd

Salt Composition

Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.2mg)

Overview Switglim MV 1mg/500mg/0.2mg Tablet ER

Diabetac Control ER, a triple-combination antidiabetic medication (1mg/500mg/0.2mg), is indicated for adult-onset type 2 diabetes management. This formulation helps regulate blood glucose. Administer Diabetac Control ER with meals, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may be adjusted based on blood sugar monitoring. Continuous use is crucial; abrupt cessation can lead to hyperglycemia, increasing the risk of complications like nephropathy, retinopathy, neuropathy, and limb loss. This medication complements a comprehensive diabetes management plan incorporating diet, exercise, and weight management as directed by your doctor. Lifestyle modifications are essential for effective diabetes control. Hypoglycemia (low blood sugar) is a common side effect; learn to identify symptoms (sweating, dizziness, headache, tremor) and treat promptly with a fast-acting glucose source (e.g., sugary snacks, juice). Alcohol consumption increases hypoglycemia risk and should be limited. Other potential side effects include altered taste, nausea, diarrhea, abdominal pain, headache, edema, blurred vision, fractures, and upper respiratory infections. Weight gain may occur. Diabetac Control ER is contraindicated in type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Inform your doctor of any pre-existing heart conditions before commencing treatment; it may be unsuitable. Pregnant or lactating women require medical consultation prior to use. Regular blood glucose monitoring and periodic blood tests (complete blood count, liver function tests) are recommended.

Uses of Switglim MV 1mg/500mg/0.2mg Tablet ER

Managing type 2 diabetes

Major Benefits of Switglim MV 1mg/500mg/0.2mg Tablet ER:

Consume this medication precisely as your physician directs, adhering to the prescribed dosage and treatment length. Ingest the entire tablet without chewing, crushing, or fracturing it. Switglim MV 1mg/500mg/0.2mg Extended-Release tablets should be administered on an empty stomach.

Common Side effects of Switglim MV 1mg/500mg/0.2mg Tablet ER:

  • Nausea
  • Diarrhea
  • Abdominal pain
  • Hypoglycemia (low blood glucose level)
  • Loss of appetite

How to use Switglim MV 1mg/500mg/0.2mg Tablet ER:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Switglim MV 1mg/500mg/0.2mg Extended-Release Tablets should be administered on an empty stomach.

How Switglim MV 1mg/500mg/0.2mg Tablet ER works:

Extended-release Switglim MV tablets (1mg/500mg/0.2mg) contain a triple-action antidiabetic formulation.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Consuming alcohol alongside Switglim MV 1mg/500mg/0.2mg Tablet ER is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

Extended-release Switglim MV tablets (1mg/500mg/0.2mg) may pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against potential dangers prior to prescription. Physician consultation is recommended.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Switglim MV tablets (1mg/500mg/0.2mg) are likely not safe for use while breastfeeding. Available human data indicates potential drug transfer to breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyUNSAFE

Employing Switglim MV 1mg/500mg/0.2mg Extended-Release tablets in individuals with kidney impairment carries a substantial risk and is best avoided. Medical advice is recommended. Furthermore, this medication is contraindicated for patients exhibiting severe renal dysfunction.

LiverLiverCAUTION

Patients with liver impairment should use Switglim MV 1mg/500mg/0.2mg Extended-Release tablets cautiously. Dosage modification of Switglim MV 1mg/500mg/0.2mg Extended-Release tablets may be necessary. Physician consultation is advised. A low initial dose of Switglim MV 1mg/500mg/0.2mg Extended-Release tablets is typically prescribed for individuals with mild to moderate hepatic dysfunction; however, its use is contraindicated in those with severe liver disease.

What if you forget to take Switglim MV 1mg/500mg/0.2mg Tablet ER :

Should you forget a Switglim MV 1mg/500mg/0.2mg Extended-Release Tablet, ingest it immediately upon remembrance. Nevertheless, if your next scheduled dose is imminent, omit the missed tablet and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Switglim MV 1mg/500mg/0.2mg Tablet ER

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Switglim MV 1mg/500mg/0.2mg Tablet ER

Switglim MV 1mg/500mg/0.2mg Extended-Release Tablets combine glimepiride, metformin, and voglibose to manage type 2 diabetes mellitus in adults. This combination improves blood glucose control when used with diet and exercise. Glimepiride stimulates insulin release from the pancreas; metformin reduces liver glucose production and enhances insulin sensitivity; and voglibose, an alpha-glucosidase inhibitor, lowers postprandial glucose. This medication is not suitable for type 1 diabetes.
Switglim MV 1mg/500mg/0.2mg ER tablets may cause common side effects including hypoglycemia, nausea, diarrhea, altered taste, flatulence, abdominal pain, headache, rash, and respiratory infections.
Switglim MV 1mg/500mg/0.2mg Tablet ER is contraindicated in patients with allergies to its components or excipients, those with moderate to severe kidney disease, and those with inflammatory bowel disease, colonic ulcerations, or underlying metabolic acidosis, including diabetic ketoacidosis.
Combining Switglim MV 1mg/500mg/0.2mg ER tablets with alcohol is unsafe. This combination can worsen low blood sugar (hypoglycemia) and raise the risk of lactic acidosis.
Switglim MV 1mg/500mg/0.2mg ER tablets can cause low blood sugar (hypoglycemia), manifesting as nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, anxiety, or shakiness. This risk increases with missed meals, alcohol consumption, excessive exercise, or concurrent use of other diabetes medications. Therefore, regular blood sugar monitoring is crucial. Always carry a quick-acting sugar source like glucose tablets, honey, or fruit juice.
Store this medication in its original, tightly closed container as directed on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Switglim MV 1mg/500mg/0.2...
123
MRP 143
13% off